Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD

Blood (2014) 124 (21): 4747.

https://doi.org/10.1182/blood.V124.21.4747.4747

Published: 2014

Journal Articles

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Christoph Driessen, MD, Dagmar Hess, MD, Thomas Pabst, MD, Sarah R Haile, Markus Joerger, MD, Roger von Moos, MD, Catherine Berset, Susanne Crowe, Hilde Rosing, PhD, Hermen S Overkleeft, Christiana Sessa, Marianne Kraus

Blood (2012) 120 (21): 2956.

https://doi.org/10.1182/blood.V120.21.2956.2956

Published: 2012

Journal Articles

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Sunil Sharma, MD, Emile Voest, MD, PhD, Nicole Hagner, MD, P.O. Witteveen, MD, PhD, Martijn Lolkema, MD, PhD, Neeraj Agarwal, MD, Sue-zette Valera, Jason Li, PhD, Derek Mires, Maria Grazia Porro, PhD, Margaret M. Woo, PharmD, Dagmar Hess, MD

Blood (2011) 118 (21): 5001.

https://doi.org/10.1182/blood.V118.21.5001.5001

Published: 2011

Journal Articles

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Dagmar Hess, MD, Nicole Hagner, MD, Sally Clive, MD, Hans Gelderblom, MD, PhD, Eva Rossmann, MD, PhD, Neeraj Agarwal, MD, Maria Grazia Porro, PhD, Thomas Hengelage, PhD, Annie St-Pierre, PhD, Lucien Gazi, PhD, Jason Li, PhD, Margaret M. Woo, PharmD, Sunil Sharma, MD

Blood (2011) 118 (21): 5007.

https://doi.org/10.1182/blood.V118.21.5007.5007

Published: 2011

Journal Articles

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

Anne Sonet, Carlos Graux, Johan Maertens, Christine-Maria Hartog, Justus Duyster, Katharina Götze, Jochen Greiner, Marie-Luise Hütter, Alois Gratwohl, Dominik Heim, Dagmar Hess, Yves Chalandon, Athos Gianella-Borradori, Narmyn Rejeb, Oliver Ottmann

Blood (2008) 112 (11): 2963.

https://doi.org/10.1182/blood.V112.11.2963.2963

Published: 2008

NARROW

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only